Citigroup
NVNO

Citigroup’s enVVeno Medical NVNO Stock Holding History

Citigroup’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10 Buy
+1
New +$11 ﹤0.01% 5740

Other funds holding NVNO

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup's NVNO Position: Q1 2026 in Review

Citigroup opened a new position in enVVeno Medical (NVNO) in Q1 2026: 1 share worth $10. The stake represents ﹤0.01% of the portfolio and ranks #5740 among its holdings.

17 funds tracked by Wall St. Rank hold NVNO as of Q1 2026.

  • Citigroup held 1 share of enVVeno Medical worth $10 as of Q1 2026.
  • enVVeno Medical was a new Citigroup position in Q1 2026.
  • enVVeno Medical made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5740 holding.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.